A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders

Susan P. Perrine, Gordon D. Ginder, Douglas V. Faller, George H. Dover, Tohru Ikuta, H. Ewa Witkowska, Shi Ping Cai, Elliott P. Vichinsky, Nancy F. Olivieri

Research output: Contribution to journalArticle

381 Citations (Scopus)

Abstract

Background: Fetal-globin (γ-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the β-globin chains that are defective or absent in patients with the β-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in γ-globin-gene expression in the developing fetus, cultured cells, and animal models. Methods: To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with β-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of γ-globin messenger RNA (mRNA) were determined before and during treatment. Results: In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of γ-globin mRNA increased twofold to sixfold. The increase in γ-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. Conclusions: In patients with β-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate β-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or β-thalassemia., Sickle cell anemia and the β-thalassemia syndromes are prevalent disorders caused by mutations affecting the adult-globin (beta-globin) chain of hemoglobin A (the chains designated as α2β2)15. Sickle cell anemia was the first disease to be characterized at the molecular level35. Definitive treatment for the underlying condition has not followed, however, except for bone marrow transplantation in the few patients for whom there are appropriate donors. Increased production or prolonged expression of fetal globin (γ-globin) in sufficient quantities can ameliorate both disorders613. Chemotherapeutic agents, including azacitidine, cytarabine, and hydroxyurea, have been…

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalNew England Journal of Medicine
Volume328
Issue number2
DOIs
StatePublished - Jan 14 1993

Fingerprint

Globins
Butyrates
Gene Expression
Thalassemia
Sickle Cell Anemia
Reticulocytes
Sickle Hemoglobin
Fetal Hemoglobin
Hemoglobin A
Azacitidine
Hemoglobinopathies
Messenger RNA
Hydroxyurea
Cytarabine
Transaminases
Bone Marrow Transplantation
Intravenous Infusions
Polymerization

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., ... Olivieri, N. F. (1993). A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders. New England Journal of Medicine, 328(2), 81-86. https://doi.org/10.1056/NEJM199301143280202

A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders. / Perrine, Susan P.; Ginder, Gordon D.; Faller, Douglas V.; Dover, George H.; Ikuta, Tohru; Witkowska, H. Ewa; Cai, Shi Ping; Vichinsky, Elliott P.; Olivieri, Nancy F.

In: New England Journal of Medicine, Vol. 328, No. 2, 14.01.1993, p. 81-86.

Research output: Contribution to journalArticle

Perrine, SP, Ginder, GD, Faller, DV, Dover, GH, Ikuta, T, Witkowska, HE, Cai, SP, Vichinsky, EP & Olivieri, NF 1993, 'A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders', New England Journal of Medicine, vol. 328, no. 2, pp. 81-86. https://doi.org/10.1056/NEJM199301143280202
Perrine, Susan P. ; Ginder, Gordon D. ; Faller, Douglas V. ; Dover, George H. ; Ikuta, Tohru ; Witkowska, H. Ewa ; Cai, Shi Ping ; Vichinsky, Elliott P. ; Olivieri, Nancy F. / A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders. In: New England Journal of Medicine. 1993 ; Vol. 328, No. 2. pp. 81-86.
@article{ee316f2ab55d43a38f9cff7c83f61a69,
title = "A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders",
abstract = "Background: Fetal-globin (γ-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the β-globin chains that are defective or absent in patients with the β-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in γ-globin-gene expression in the developing fetus, cultured cells, and animal models. Methods: To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with β-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of γ-globin messenger RNA (mRNA) were determined before and during treatment. Results: In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of γ-globin mRNA increased twofold to sixfold. The increase in γ-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. Conclusions: In patients with β-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate β-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or β-thalassemia., Sickle cell anemia and the β-thalassemia syndromes are prevalent disorders caused by mutations affecting the adult-globin (beta-globin) chain of hemoglobin A (the chains designated as α2β2)1–5. Sickle cell anemia was the first disease to be characterized at the molecular level3–5. Definitive treatment for the underlying condition has not followed, however, except for bone marrow transplantation in the few patients for whom there are appropriate donors. Increased production or prolonged expression of fetal globin (γ-globin) in sufficient quantities can ameliorate both disorders6–13. Chemotherapeutic agents, including azacitidine, cytarabine, and hydroxyurea, have been…",
author = "Perrine, {Susan P.} and Ginder, {Gordon D.} and Faller, {Douglas V.} and Dover, {George H.} and Tohru Ikuta and Witkowska, {H. Ewa} and Cai, {Shi Ping} and Vichinsky, {Elliott P.} and Olivieri, {Nancy F.}",
year = "1993",
month = "1",
day = "14",
doi = "10.1056/NEJM199301143280202",
language = "English (US)",
volume = "328",
pages = "81--86",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "2",

}

TY - JOUR

T1 - A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders

AU - Perrine, Susan P.

AU - Ginder, Gordon D.

AU - Faller, Douglas V.

AU - Dover, George H.

AU - Ikuta, Tohru

AU - Witkowska, H. Ewa

AU - Cai, Shi Ping

AU - Vichinsky, Elliott P.

AU - Olivieri, Nancy F.

PY - 1993/1/14

Y1 - 1993/1/14

N2 - Background: Fetal-globin (γ-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the β-globin chains that are defective or absent in patients with the β-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in γ-globin-gene expression in the developing fetus, cultured cells, and animal models. Methods: To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with β-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of γ-globin messenger RNA (mRNA) were determined before and during treatment. Results: In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of γ-globin mRNA increased twofold to sixfold. The increase in γ-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. Conclusions: In patients with β-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate β-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or β-thalassemia., Sickle cell anemia and the β-thalassemia syndromes are prevalent disorders caused by mutations affecting the adult-globin (beta-globin) chain of hemoglobin A (the chains designated as α2β2)1–5. Sickle cell anemia was the first disease to be characterized at the molecular level3–5. Definitive treatment for the underlying condition has not followed, however, except for bone marrow transplantation in the few patients for whom there are appropriate donors. Increased production or prolonged expression of fetal globin (γ-globin) in sufficient quantities can ameliorate both disorders6–13. Chemotherapeutic agents, including azacitidine, cytarabine, and hydroxyurea, have been…

AB - Background: Fetal-globin (γ-globin) chains inhibit the polymerization of hemoglobin S (sickle hemoglobin) and can functionally substitute for the β-globin chains that are defective or absent in patients with the β-thalassemias. Identifying safe mechanisms to stimulate fetal-hemoglobin production is therefore of great interest. Previous studies have shown that administering butyrate selectively stimulates the promoter of the human fetal-globin gene and leads to increases in γ-globin-gene expression in the developing fetus, cultured cells, and animal models. Methods: To determine whether butyrate can stimulate fetal-globin production in humans, we treated three patients (3 to 13 years old) with sickle cell anemia and three patients (7 to 27 years old) with β-thalassemia syndromes with a short course of intravenous infusions of arginine butyrate. The drug was infused continuously for either two or three weeks; the initial dose was 500 mg per kilogram of body weight per day. Globin-chain ratios, proportions of reticulocytes producing hemoglobin F (F reticulocytes), and levels of γ-globin messenger RNA (mRNA) were determined before and during treatment. Results: In all six patients, fetal-globin synthesis increased by 6 to 45 percent above pretreatment levels (P<0.01). The proportion of F reticulocytes increased about twofold, and the level of γ-globin mRNA increased twofold to sixfold. The increase in γ-globin synthesis led to improvement in the globin-chain ratios in the patients with thalassemia. The treatment of one patient was extended for seven weeks, and her hemoglobin level increased from 4.7 to 10.2 g per deciliter (2.9 to 6.3 mmol per liter). Side effects were minimal; one patient had a transient increase in serum aminotransferase concentrations. Conclusions: In patients with β-hemoglobinopathies butyrate, a natural fatty acid, can significantly and rapidly increase fetal-globin production to levels that can ameliorate β-globin disorders. Further trials of this class of compounds are warranted to determine long-term tolerance and efficacy in patients with sickle cell anemia or β-thalassemia., Sickle cell anemia and the β-thalassemia syndromes are prevalent disorders caused by mutations affecting the adult-globin (beta-globin) chain of hemoglobin A (the chains designated as α2β2)1–5. Sickle cell anemia was the first disease to be characterized at the molecular level3–5. Definitive treatment for the underlying condition has not followed, however, except for bone marrow transplantation in the few patients for whom there are appropriate donors. Increased production or prolonged expression of fetal globin (γ-globin) in sufficient quantities can ameliorate both disorders6–13. Chemotherapeutic agents, including azacitidine, cytarabine, and hydroxyurea, have been…

UR - http://www.scopus.com/inward/record.url?scp=0027078611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027078611&partnerID=8YFLogxK

U2 - 10.1056/NEJM199301143280202

DO - 10.1056/NEJM199301143280202

M3 - Article

C2 - 7677966

AN - SCOPUS:0027078611

VL - 328

SP - 81

EP - 86

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -